학술논문
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen
Document Type
article
Author
Raymond, Stéphanie; Nicot, Florence; Pallier, Coralie; Bellecave, Pantxika; Maillard, Anne; Trabaud, Mary Anne; Morand-Joubert, Laurence; Rodallec, Audrey; Amiel, Corinne; Mourez, Thomas; Bocket, Laurence; Beby-Defaux, Agnès; Bouvier-Alias, Magali; Lambert-Niclot, Sidonie; Charpentier, Charlotte; Malve, Brice; Mirand, Audrey; Dina, Julia; Le Guillou-Guillemette, Hélène; Marque-Juillet, Stéphanie; Signori-Schmuck, Anne; Barin, Francis; Si-Mohamed, Ali; Fenoel, Véronique Avettand; Roussel, Catherine; Calvez, Vincent; Saune, Karine; Marcelin, Anne Geneviève; Rodriguez, Christophe; Descamps, Diane; Izopet, Jacques; Lagier, E; Roussel, C; Le Guillou-Guillemette, H; Alloui, C; Bettinger, D; Pallier, C; Fleury, H; Reigadas, S; Bellecave, P; Recordon-Pinson, P; Payan, C; Vallet, S; Vabret, A; Dina, J; Henquell, C; Mirand, A; Bouvier-Alias, M; de Rougemont, A; Dos Santos, G; Morand, P; Signori-Schmuck, A; Bocket, L; Rogez, S; Andre, P; Tardy, JC; Trabaud, MA; Tamalet, C; Delamare, C; Montes, B; Schvoerer, E; Ferré, V; André-Garnier, E; Cottalorda, J; Guinard, J; Guiguon, A; Descamps, D; Brun-Vézinet, F; Charpentier, C; Visseaux, B; Peytavin, G; Krivine, A; Si-Mohamed, A; Avettand-Fenoel, V; Marcelin, AG; Calvez, V; Lambert-Niclot, S; Soulié, C; Wirden, M; Morand-Joubert, L; Delaugerre, C; Chaix, ML; Amiel, C; Schneider, V; Giraudeau, G; Defaux, A Beby-; Brodard, V; Maillard, A; Plantier, JC; Chaplain, C; Bourlet, T; Fafi-Kremer, S; Stoll-Keller, F; Schmitt, MP; Barth, H; Yerly, S; Poggi, C; Izopet, J; Raymond, S; Barin, F
Source
Clinical Infectious Diseases. 66(10)
Subject
Language
Abstract
BackgroundMinority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t)ide reverse transcriptase inhibitors and NNRTIs and to assess their influence on the virological response (VR).MethodsAll the subjects, 541 HIV-1-infected patients started a first-line regimen containing rilpivirine. VR was defined as a HIV-1 RNA load 20% in 29% of samples. We identified 43 (8.8%) and 36 (7.4%) patients who harbored rilpivirine-resistant variants with a 1% sensitivity threshold according to the French National Agency for Research on AIDS and Viral Hepatitis and Stanford algorithms, respectively. The VR was 96.9% at month 12. Detection of minority rilpivirine resistant variants was not associated with virological failure (VF). Multivariate analysis indicated that VF at month 12 was associated with a CD4 count